Economic Evaluation alongside the Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen in Extreme Preterm Babies
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
To conduct an economic evaluation alongside the placebo-controlled trial of selective early treatment of patent ductus arteriosus with ibuprofen in extreme preterm babies.
Design
Within-trial economic evaluation alongside a multicentre, randomized, masked, placebo-controlled trial.
Setting
Thirty-two UK tertiary neonatal intensive care units.
Sample
Babies born between 23 +0 to 28 +6 weeks’ gestation, less than 72 hours old and confirmed by echocardiography to have a large PDA.
Methods
A cost-effectiveness analysis was conducted from the National Health Service (NHS) and NHS and Personal Social Services perspectives. Nonparametric bootstrapping was used to estimate incremental costs and outcomes which were reported as cost-effectiveness acceptability curves.
Main outcome measures
Cost per additional major outcome averted.
Results
Ibuprofen is less costly with an average cost per participant of £126,465 compared to £133,260 (-£6,808 (95% CI: £-17,154 to £3,537) for placebo. But it is less effective in terms of major outcomes averted with an absolute effect difference of 0.054 (95% CI: -0.014 to 0.121). The differences in mean cost were mainly attributable to the costs of high dependency care (£2,345, 95% CI -£3,435 to £8,126) and intensive care (£6,718, 95% CI - £12,627 to £26,063) which were higher in the placebo arm. The incremental cost-effectiveness ratio was estimated at £126,846 for an additional case of death, or severe or moderate bronchopulmonary dysplasia avoided by 36 weeks of post-menstrual age.
Conclusions
Based on the evidence from this trial, ibuprofen would not be recommended. There is insufficient evidence to suggest that any of the observed detrimental impact on effectiveness would be outweighed by the opportunity cost associated of any saving in costs.
